Updates are available Correction dated 2019-01-10

Article History

First Online: 20 October 2018

Change Date: 10 January 2019

Change Type: Correction

Change Date: 10 January 2019

Change Type: Correction

Change Details: The original publication of this article is missing a disclosure statement for Dr. Amalia Londono Tobon.

Change Details: The original publication of this article is missing a disclosure statement for Dr. Amalia Londono Tobon.

Compliance with ethical standards

:

: Dr. Londono Tobon has nothing to disclose.Dr. Newport has received research support from Eli Lilly, Glaxo SmithKline (GSK), Janssen, National Alliance for Research on Schizophrenia and Depression (NARSAD), National Institutes of Health (NIH), Takeda Pharmaceuticals, and Wyeth. He has served on speakers’ bureaus and/or received honoraria from Astra-Zeneca, Eli Lilly, GSK, Pfizer, and Wyeth. He has served on advisory boards for GSK, Janssen, and Sage Therapeutics. He has never served as a consultant to any biomedical or pharmaceutical corporations. Neither he nor family members have ever held equity positions in biomedical or pharmaceutical corporations.Dr. Nemeroff has received research support from the National Institutes of Health (NIH) and Stanley Medical Research Institute. He has served on scientific advisory boards for the American Foundation for Suicide Prevention (AFSP), Anxiety and Depression Association of America (ADAA), Bracket (Clintara), Brain and Behavior Research Foundation, Laureate Institute for Brain Research (LIBR), Skyland Trail, and Xhale, on the board of directors for AFSP, ADAA, and Gratitude America, and as a consultant (within the last 3 years) to Bracket (Clintara), Fortress Biotech, Intra-Cellular Therapies Inc., Janssen Research & Development LLC, Magstim Inc., Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Taisho Pharmaceutical Inc., Takeda Pharmaceuticals, TC MSO Inc., and Xhale. He has stock holdings with Abbvie, Antares, BI Gen Holdings Inc., Celgene, Corcept Therapeutics Pharmaceuticals Company, OPKO Health Inc., Seattle Genetics, and Xhale. He has received honoraria, royalties, and expert witness fees from various sources. His income sources or equity of $10,000 or more include American Psychiatric Publishing, Bracket (Clintara), CME Outfitters, Intra-Cellular Therapies Inc., Magstim, Takeda Pharmaceuticals, and Xhale. He holds patents for Method and devices for transdermal delivery of lithium (US 6,375,990B1), method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), and Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2).

: This article does not contain any studies with human or animal subjects performed by any of the authors.